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Abstract
Objectives: To assess the use of three commonly prescribed psychotropic medications in youth placed in residential care (RC).
Methods: Participants were youth aged 0–20 years placed in RC institutions at least once during 2016. Data on filled
prescriptions were taken from the Norwegian Prescription Database to compare the use of antidepressants, antipsychotics,
and stimulants in RC with the age- and gender-adjusted general child population (GenPop) and how this co-varied with
reasons for RC placement, age, and gender.
Results: One thousand eight hundred fifty-six children and adolescents were identified in RC, with mean age 14 (range 0–20
years), 46% girls, 81% ‡ 13 years. Among those, 423 or 23% used any of the 3 psychotropics, which was significantly more
than the 3.7% in GenPop. The prevalence ratios RC/GenPop were 6.6 for antidepressants, 17.9 for antipsychotics, and 4.4 for
stimulants. The median number of days per year for the dispensed defined daily doses varied from 8.3 to 244.0 for the
different antipsychotics, indicating short time use for most of the people. Polypharmacy was not frequent in RC, as only 26%
used ‡2 classes of medication, but still significantly more frequent than the 10% in GenPop. Youth placed in RC for serious
behavior problems had significantly higher use of stimulants than those with other placement reasons. Psychotropics were
not used below age 6 years, and although the use of antidepressants and antipsychotics overall increased with age, stimulants
were mostly used by 6–16-year olds. The girl/boy ratio for any psychotropic medication use in RC was 1.4 (95% confidence
interval [95% CI]: 1.1–1.6), significantly higher than the corresponding ratio in GenPop: 1.0 (95% CI: 0.9–1.0).
Conclusion: The present findings do not necessarily suggest an overtreatment with medication in RC. However, the frequent
short-term use of antipsychotics, presumably for non-psychotic symptoms, is a concern, as it may reflect that the youth are
not provided with the recommended first-line psychological treatments.
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Introduction
Studies of youth within different sectors of the U.S. childwelfare system have reported high rates of psychiatric and/or
neurodevelopmental disorders (Garland et al. 2001; Turney and
Wildeman 2016). Similar high rates were confirmed in a large
British study, with a significantly higher prevalence among those in
residential care (RC) (71%) compared with foster care (39%) (Ford
et al. 2007). In a recent representative study using a structured
psychiatric interview, 76% of Norwegian adolescents in RC were
reported to have at least one psychiatric disorder ( Jozefiak et al.
2016). Anxiety- and depressive disorders were more prevalent
than behavioral disorders, with a high comorbidity between the
two main types of disorders. The high number of psychiatric
disorders is not surprising, given the reasons for placement in RC,
that is, severe psychosocial strain, neglect, maltreatment, and/or
serious behavioral problems, all represent risk factors for mental
disorders (Gilbert et al. 2009; Green et al. 2010; Hunt et al. 2017).
Of note, although a great majority of the adolescents in RC
were diagnosed with a psychiatric disorder, only 38% had re-
ceived help from the child and adolescent mental health services
( Jozefiak et al. 2016).
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As many major psychiatric disorders have an onset before
age 18, medication has been increasingly utilized in youth, but,
as pointed out in an important review about 10 years ago, psy-
chopharmacologic treatments in pediatric patients also raised
concerns regarding a potential overtreatment, without adequate
data regarding the pediatric efficacy and safety of psychotropic
classes (Correll et al. 2011). The authors still concluded that for
three frequently used classes, that is, stimulants, antidepressants,
and antipsychotics: ‘‘effect sizes against placebo have typically
been at least moderate, with most numbers-needed-to-treat well
below 10 for response, indicating clinical significance as well.’’
In a more recent review, stimulants, selective serotonin reuptake
inhibitors (SSRIs), and antipsychotics were found to have docu-
mented efficacy for attention-deficit/hyperactivity disorder (ADHD),
pediatric depression/anxiety disorders, and childhood-onset schi-
zophrenia, respectively (Giles and Martini 2016). The review also
reported that the evidence base for providing antipsychotics to
youth with bipolar mania and autism spectrum disorders (ASD) had
grown, and that atypical antipsychotics were used in the pediatric
population for the management of aggressive and oppositional
behaviors, although there were concerns regarding adverse reac-
tions. Further, a study of dosage and prevalence of antipsychotic
prescriptions in Scandinavia from 2006 to 2016 found a steady
trend of low or decreasing dosages for the majority of commonly
used antipsychotics, suggesting that these are prescribed outside
their main indications (e.g., as anxiolytics, hypnotics or sedatives)
(Hojlund et al. 2019).
The use of psychotropic medication has been found to vary con-
siderably between countries, as also confirmed in the recent inter-
national review, where U.S. youth consistently were found among the
high users (Piovani et al. 2019). The review reported that the global
random-effect pooled prevalence of psychotropic drug prescriptions
among youth was 15.3& (95% confidence interval [CI] 7.6&–
25.7&) for ADHD medications, 6.4& (95% CI 4.3–8.7) for antide-
pressants, and 5.5& (95% CI 3.6–7.8) for antipsychotics. Systematic
monitoring was found to be lacking in most countries, and the authors
noted that prevalence data by gender were often missing.
In a study of U.S. national annual prescribing patterns of the
same three psychotropic classes, data from different age groups
were analyzed from a national longitudinal prescription database
(n = 6,351,482) (Sultan et al. 2018). The total annual percentage of
prescriptions filled by youth for any of the three classes was by
age 3–5 years: 0.8%, 6–12 years: 5.4%, 13–18 years: 7.7%, and 19–
24 years: 6.0%. Stimulant use was highest for older children (age
11 = 5.7%). Antidepressant use tended to increase with age and
was highest for young adults (age 24 = 4.8%). Annual antipsycho-
tic prescription percentages were lower than antidepressant or
stimulant percentages for all age groups, with a peak in adoles-
cence (age 16 = 1.3%). Annual stimulant and antipsychotic per-
centages for males were higher than corresponding percentages for
females, but they converged for young adults.
Within the child welfare system, there is still a paucity of
studies on psychotropic medication use, and systematic data on
patterns of medication treatment, with a particular weight on the
use of concomitant drugs has been called for in the literature
(Raghavan et al. 2005; Zito et al. 2008b). In the following, we
therefore include relevant literature from the last two decades.
An early report on Medicaid-enrolled youth in foster-care raised
concern as 30% had received psychotropic medications (dosReis
et al. 2001). Following up with a later study, the most frequently
used medications were antidepressants (57%), ADHD drugs (56%),
and antipsychotics (53%) (Zito et al. 2008b) with frequent poly-
pharmacy, as 41% of the youth in foster care received ‡3 differ-
ent classes of psychotropics, and the authors were concerned, as
polypharmacy increases the risk for adverse reactions (Bogler et al.
2019). Later studies have corroborated the high prevalence of poly-
pharmacy and demonstrated subgroup differences, such as higher
polypharmacy in boys compared with girls, and in group homes
compared with foster homes (Keast et al. 2019).
Although it is difficult to accurately compare the prevalence
of psychotropic medications due to different jurisdictions and dif-
ferent years and age groups reported in the literature, the prevalence
rates for the use of at least one psychotropic agent in U.S. child
welfare has been found to be as high as 37% in older youth in foster
care (McMillen et al. 2004), and even used by the majority of the
study participants in therapeutic foster care (67%) and group homes
(77%) (Breland-Noble et al. 2004).
A recent review on psychotropic medications for different
groups of highly vulnerable children in the United States concluded
that they generally receive numerous psychotropic medications.
This includes high rates of polypharmacy, off-label use, and long-
term use, typically in the absence of adjunctive psychosocial in-
terventions (McLaren et al. 2018). The authors further reported
medication use among 76%–91% of the children within residential
treatment facilities, compared with 7.5% in the general child
population, and 13%–40% in children placed in foster care.
In a literature search on psychotropic medication use in child
welfare, the retrieved studies were generally from the United
States, as presented earlier, and none were from developing coun-
tries. We found only one Scandinavian study, showing that about
one-third of youth institutionalized for serious behavioral problems
in two Swedish adolescent units were given psychopharmaco-
logical treatment (Anckarsäter et al. 2007). This lack of studies
is unfortunate as Scandinavian countries have prescription data-
bases available for all citizens, providing opportunities to inform
on representative populations.
To the best of our knowledge, representative Scandinavian studies
of the use of antidepressants, antipsychotics, and stimulants have not
been investigated in the child welfare system. The aim of the present
study was, therefore, to investigate the use of these three commonly
used classes of psychotropic medication in a representative Norwe-
gian cohort of youth placed in RC institutions, including how this co-
varied with reasons for placement, age, and gender.
Methods
Study population
Participants were all children and adolescents aged 0–20 years
placed in RC institutions under the Norwegian Directorate for Chil-
dren, Youth and Family Affairs, Child Welfare Services (BUFDIR) at
least once during 2016 due to one or more of the following reasons for
placement: neglect, emergency placement, serious behavioral prob-
lems of high and low degree, and/or substance abuse. This directorate
is responsible for all RC institutions in Norway except for those in the
municipality of Oslo, which administers its own institutions. Conse-
quently, 80% of Norwegian RC institutions were included in the
present study. Available background data on the participants included
gender, age, and reasons for placement in RC institutions.
Prescription drug data
For the RC population, data on all filled prescriptions during
2016 were available from the Norwegian Prescription Database
(NorPD) for each individual. The drugs were classified according to
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the Anatomical Therapeutic Chemical (ATC) classification system,
version 2020 (World Health Organization [WHO] 2020) avail-
able from https://www.whocc.no/atc_ddd_index_and_guidelines/
guidelines.
We had information on ATC code and month of dispensing. For
the general population we had information on number of users of
the relevant ATC codes in 2016 in 1-year age groups for boys and
girls. The following classes of psychotropic medications were
studied: antidepressants (ATC N06A), antipsychotics (ATC N05A,
except N05AN01 [lithium]), and stimulants (ATC N06BA), de-
fined as at least one prescription of one of the relevant psychotropic
medication classes during 2016. In Norway, the number of chil-
dren and adolescents treated with lithium or other mood stabilizers
were low (Bramness et al. 2009; Furu et al. 2018), and we were
therefore unable to report these frequencies in our population. The
quantity dispensed for each drug prescription is expressed by the
defined daily dose (DDD) measure, which is ‘‘the assumed average
maintenance dose per day for a drug used for its main indication
in adults’’ (WHO 2020).
Statistics
We compared the prevalence of dispensed psychotropic medi-
cation in RC with the age- and gender-corrected prevalence in the
general child population (GenPop). We also compared boys and
girls within and between the two populations. Means, percentages,
and prevalence ratios (PRs) with 95% CIs are presented. PR = (nRC/
NRC)/(nGenPop/NGenPop), where n and N denote number of users and
number of individuals, respectively, in the two populations. Age-
and gender correction was done by using the ‘‘ageadjust.direct’’
function in the R-package epitools, with the study population as
reference population (1 year age groups). PRs between girls and
boys and between RC and GenPop, with 95% CIs were computed
by using the ‘‘riskscoreci’’ function in the ‘‘PropCIs’’ package in R
(R Development Core Team 2020). p-Values for PRs in the study
population were computed by using Fisher’s exact test. When the
numerator and/or the denominator of the PR was age- and gender
corrected, the uncertainty involved in the age- and gender correc-
tion was taken into account by using a simulation approach (see
Supplementary Data for details). We calculated the median, lower,
and upper interquartile of DDDs per person per year, thereby
estimating the median number of days for which each person was
treated with the different psychotropic medications during 2016.
The chi-square test was used to compare polypharmacy in RC
with GenPop, and medication use with reasons for placement
in RC.
Ethics
The study was approved by The Regional Committee for Med-
ical Research Ethics in South-Eastern Norway (REK), Norwegian
Centre for Research Data, and the Norwegian Data Inspectorate
without informed consent under given conditions. These conditions
included data only being handled by one of the authors (V.H.) on a
secure server and destroying the linking key to ensure no possibility
for back identification of individuals. Further, data were available
in 1-year age groups, but are presented in larger intervals (0–5, 6–
12 years, etc.) to ensure anonymity, and numbers less than N = 5 are
not shown. A personal identification number provided by BUFDIR
allowed a linkage via the Norwegian National Register to the
NorPD prescription data (reference: REK 2017/1637).
Results
One thousand eight hundred fifty-six youth were identified
in RC with mean age 14 years (range 0–20 years), 46% girls,
81% ‡ 13 years. Among those, 423 children (23% [95% CI: 20.9–
24.8]) dispensed at least one of three psychotropic medications
(antidepressants, antipsychotics, or stimulants), which was signif-
icantly more than the 3.7% in the general child population (PR: 6.1
[95% CI: 5.6–6.8]).
In RC, polypharmacy was not frequent, as 74% (n = 312) used
one class of medication, 24% (n = 102) used two, and 2% (n = 9)
used three classes, although significantly more frequent than in
GenPop, where 90% (n = 27,791), 9.5% (2929), and 0.5% (153)
of the psychotropic drug users used one, two, and three classes,
respectively ( p < 0.0001). Figure 1 displays the use of the three
psychotropics and their overlap in boys and girls in RC. Although
the combination of antidepressants and antipsychotics was most
common among girls, the combination of antipsychotics and stim-
ulants was most common among boys.
In RC, antidepressants were used by 8.9%, antipsychotics by
10.9%, and stimulants by 9.6%. In GenPop the corresponding num-
bers were significantly lower: 0.7%, 0.4%, and 1.5%, respectively,
with PRs between RC and GenPop: 6.6 (95% CI: 5.5–7.8) for
antidepressants, 17.9 (95% CI: 15.1–21.2) for antipsychotics, and
4.4 (95% CI: 3.7–5.2) for stimulants.
When comparing reasons for placement in RC (e.g., neglect,
emergency placement, serious behavioral problems of high and
low degree, and-/or substance abuse), overall medication use was
significantly different ( p = 0.02), mainly due to higher use of stim-
ulants ( p < 0.0001) among those placed for serious behavior prob-
lems. The percentage using stimulants was highest in those placed
for serious behavioral problems of a high degree (22.3; 95% CI
15.1–31.8) and lowest in those placed for substance abuse (5.2;
2.2–11.6). For antipsychotics it was the other way round—the
percentage was highest in those placed for substance abuse (18.8;
12.2–27.2) and second lowest in those placed for serious behavioral
problems of high degree (10.6; 5.9–18.5). The lowest antipsychotic
use was in those with emergency placement (10.4; 8.4–13.0). The
pattern for antidepressants was similar to that of antipsychotics.
Both for antidepressants and antipsychotics, the CIs for all five
placement groups overlapped, whereas for stimulants both the high
and low degree of serious behavioral problems groups had signif-
icantly higher use than the emergency placement, neglect, and
substance abuse groups.
None of the children aged 0–5 years in RC used any of the
investigated psychotropic medications. The use of any of the 3
psychotropics increased with age and was 13.9% among 6–12-year
olds, 23.2% among 13–16-year olds, and 31.1% among 17–20-year
olds, which was about 6 times higher than GenPop in all age groups.
The girl/boy ratio for any psychotropic medication use in RC was
1.4 (95% CI: 1.1–1.6), significantly higher than the corresponding
ratio in GenPop: 1.0 (95% CI: 0.9–1.0).
In RC, antidepressants were not used under age 13 years, but
increased with age thereafter (7.6% and 14.5% in the two older age
groups). The use of antipsychotics in RC increased with age group
(5.7%, 9%, and 16.8%, respectively), and the ratio RC/GenPop
was particularly high (33.0) among 6–12-year olds and about 18 in
the 2 older age groups. In RC, 13.1% used stimulants among 6–12
olds (ratio RC/GenPop: 5.9) with a 12.7% and 8.9% use in the
2 oldest age groups (and ratios RC/GenPop of about 4).
Gender differences were found between the three classes,
with significantly more antidepressants and antipsychotics in girls
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compared with boys, and the reverse pattern found for stimulants
(girl/boy ratios of 3.4, 2.0, and 0.5, respectively, all p’s < 0.001).
Please see Supplementary Tables S1–S3 for details on the use of
antidepressants, antipsychotics, and stimulants in RC, including
ratios RC/GenPop for each age group for all participants, and by
gender, as well as girl/boy ratios by age group for the different
psychotropics.
Among the 423 in RC who were dispensed psychotropic medi-
cation, 39.0% used antidepressants, 47.3% antipsychotics, and
42.1% stimulants. Among antidepressants, SSRIs were used by
83.0%, and the rest used other antidepressants than SSRIs (ATC-
code N06A). Among stimulants, methylphenidate was used by
73.6% in RC (the rest used lisdexamfetamine or atomoxetine).
Details of the different antipsychotics used in RC in boys and
girls are presented in Table 1, including data for the different age
groups when possible (N > 5). The median number of days per year
with dispensed DDDs was highest for olanzapine and aripiprazole,
and lowest for quetiapine, risperidone, and clorprotixene, indicat-
ing that at least these three latter antipsychotics were dispensed
sporadically. For all antipsychotics, very few of the children
(N = 11) in RC were dispensed DDDs, indicating use all year. There
were similar median DDDs with overlapping interquartile ranges
between age groups, and between girls and boys.
Discussion
The present study compared the use of antidepressants, anti-
psychotics, and stimulants among youth placed in RC institutions
with the age- and gender-corrected general population (GenPop).
Nearly 1 in 4 youth in RC (23%) used at least 1 of these psycho-
tropics, which was significantly more than the GenPop (3.7%). This
high and disproportionate use in RC is in line with findings from
Table 1. Dispensed Antipsychotics for Boys and Girls in Residential Care At Least Once in 2016,
Including Median Number of Days Per Year with Dispensed Defined Daily Doses and Interquartile Range
Age DDD (mg)
N Median DDD (IQR)
Boys Girls Boys Girls
Clorprotixene (Truxal) 0–20 300 6 23 9 (6–14) 8 (5–12)
Aripiprazole (Abilify) 0–20 15 13 19 149 (56–168) 65 (37–205)
13–16 93 (56–196) 75 (19–261)
17–20 168 (126–168) 61 (42–182)
Risperidone (Risperdal) 0–20 5 29 21 44 (26–78) 13 (4–38)
6–12 19 (8–32)
13–16 61 (44–118) 10 (5–18)
17–20 50 (20–88) 21 (6–68)
Quetiapine (Seroquel) 0–20 400 31 84 25 (12–38) 29 (6–76)
13–16 25 (19–31) 31 (6–80)
17–20 22 (12–38) 29 (6–69)
Olanzepine (Zyprexa) 0–20 10 7 23 224 (98–315) 98 (56–175)
For age groups with N > 5, median DDD (IQR) is also reported.
DDD, defined daily dose; IQR, interquartile range.
FIG. 1. The use of different psychotropics and their overlap in boys and girls in residential care. Numbers below 5 are shown as 5 to
avoid identification of the few youths with combinations of drugs. Some numbers above 5 are adjusted correspondingly to make the total
N per drug class correct. No number above 5 deviates with more than –2 from the true number.
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previous medication studies in the child welfare system (Raghavan
et al. 2005; Zito et al. 2008b; McLaren et al. 2018) and could result
from the increased number of mental disorders reported in this
vulnerable population (Garland et al. 2001; Ford et al. 2007;
Jozefiak et al. 2016; Turney and Wildeman 2016).
Among the youth in RC who used antidepressants, 83% dis-
pensed SSRIs, the same proportion as recently reported among
Danish youth on antidepressants (81.8% on SSRIs) (Bachmann
et al. 2016), and in line with a population-based multi-national
comparison analysis of antidepressants (in year 2000), where SSRIs
predominated in the United States, Denmark, and the Netherlands
(Zito et al. 2006). The high proportion on SSRIs among antide-
pressant users is encouraging, as a recent meta-analysis reported
this to be more beneficial than placebo in treating anxiety and
depressive disorders in children and adolescents (Locher et al.
2017). However, the author underlined that the benefit was
small and disorder specific, with a larger drug-placebo differ-
ence for anxiety disorders than for other conditions. Response to
placebo was large, especially in depressive disorders, and severe
adverse events were significantly more common with SSRIs than
placebo.
Among those who used psychotropics in RC (n = 423), 47% used
antipsychotics, somewhat fewer than among U.S. youth in foster
care, where 53% (Zito et al. 2008b) and 65% (Linares et al. 2013) of
those medicated were on antipsychotics. In our study, the median
number of days on DDDs generally indicated sporadic or short time
use of the antipsychotics, most likely indicating that these were
prescribed outside their main indications. They may have been
prescribed to treat aggression, in line with reports of antipsychotics
being frequently used for this purpose (Daviss et al. 2016), and/or to
reduce anxiety, sedation or to induce sleep (Gjerden et al. 2017).
This frequent use of antipsychotics in RC, outside their main in-
dications, is a concern, as it may suggest that this population is not
provided with the recommended first-line psychological treatments
for aggressive behaviors (Connor et al. 2006), anxiety (Zhou et al.
2019) and sleep disorders (Bruni et al. 2018). The median number
of days was particularly low for clorprotixene, risperidone, and
quetiapine (both boys and girls dispensed DDDs <44 days).
Olanzapine and aripiprazole were dispensed for longer periods
(median number of days boys: 224, 149 days; girls: 98, 65 days,
respectively), but overall somewhat shorter than the 180 and 240
median days reported for Medicaid insured youth and youth in
foster care, respectively (Burcu et al. 2014). It is possible that youth
dispensing antipsychotics for longer periods were treated for their
main indications: schizophrenia, bipolar disorders, or aggression
associated with ASD, but as these are rare conditions, it is unlikely
that they explain all of this use. Indeed, a national Norwegian study
on the use of antipsychotic drugs in 2010 found that children and
adolescents who used antipsychotic drugs were predominantly
diagnosed with nonpsychotic mental disorders, such as neurode-
velopmental disorders among boys and anxiety- or depression
disorders among girls (Nesvag et al. 2016), all of which were found
to be highly prevalent in the national Norwegian study of adoles-
cents in RC (Jozefiak et al. 2016).
Among stimulants used in RC, 73% of the youth dispensed
methylphenidate (20% atomoxetine, 16% lisdexamfetamine),
lower than in two European population-based studies, where >90%
and 98%, respectively, of youth with ADHD used methylphenidate
(Garbe et al. 2012; Oerbeck et al. 2020). Still, that which most
used methylphenidate in RC suggests that the clinicians follow the
European National Institute for Health and Care Excellence (NICE)
guidelines (NG87) that only recommend atomoxetine when psy-
chostimulants are not tolerated or to non-responders (National
Institute for Health and Care Excellence 2018).
In the present study, 74% of the youth in RC used only one class
of psychotropic medications and 26% used ‡2 classes. The com-
bination of antidepressants and antipsychotics was most common in
girls and stimulants and antipsychotics among boys, somewhat
different from previous studies where polypharmacy was more
likely in males (Safer et al. 2003; dosReis et al. 2005; Keast et al.
2019). Although polypharmacy in RC was significantly more fre-
quent than in the GenPop (90% on one class of psychotropic
medication), the numbers were considerably lower than rates re-
ported in a U.S. study of children in foster care, where 72% were
prescribed two or more psychotropic medications (41% ‡ 3) (Zito
et al. 2008b). This U.S.–European discrepancy is also in line with
international findings reported from the general child population,
where concomitant psychotropic use in the United States was three
times as frequent as in Germany and twice as frequent as that in
the Netherlands (Zito et al. 2008a), most likely a consequence of
the large variability across countries in prescribing medication for
child and adolescent psychiatric disorders (Vitiello 2008).
When comparing reasons for placement in RC, no apparent
explanations for medication use were found, apart from the higher
use of stimulants among those referred for serious behavior prob-
lems, in line with the effect that stimulants have on disruptive
disorders, whether on ADHD alone or with the often comorbid
oppositional defiant and conduct disorders (Connor et al. 2002;
Pringsheim et al. 2015). Also, stimulant use was least frequent for
those placed in RC for reasons of substance abuse, a positive
finding in line with the NICE guidelines (National Institute for
Health and Care Excellence 2018).
In the present study, none of the psychotropics were used during
preschool years (age group 0–5 years) in either population, but from
age 6 years onward, the overall use of psychotropics increased with
age. Our finding contrasted with two U.S. studies, where 1.2% of
children 4 years or younger received at least 1 psychotropic drug,
according to Medicaid data (Garfield et al. 2015), and *12% of
children age 6 and younger in foster care for 365 days or more re-
ceived at least 1 psychotropic medication over the 3-year study period
(dosReis et al. 2014). These prescription rates worried the authors due
to the limited evidence supporting safety or efficacy in this age group.
As there was no reported use of psychotropics among the preschoolers
in our study, we have no such concerns for this particular population.
However, the complete lack of use could also suggest that a few
preschoolers are provided with sufficient psychiatric health services.
Of note was that antidepressants were not used in RC £12 years, but
the high use of antidepressants from age 13 years and onward, and the
high use of stimulants in the two medium age groups (6–16 years) is in
line with previous findings (Olfson et al. 2002; Piovani et al. 2019).
We found that girls in RC overall used significantly more psy-
chotropic medication than boys, contradicting earlier findings in the
literature where boys constitute the majority (Zima et al. 1999; Ra-
ghavan et al. 2005; Zito et al. 2008b). However, in line with known
epidemiological patterns for antidepressants and stimulants (Linares
et al. 2013; Steinhausen and Bisgaard 2014; Sultan et al. 2018;
Piovani et al. 2019; Barczyk et al. 2020; Zito et al. 2020), we found
that girls in RC used more medication indicated for anxiety and
depression, whereas boys used more stimulants, for which ADHD is
the main indication. We also found that girls in RC used more an-
tipsychotics than boys, in contrast to the general finding of higher use
in boys, both in the general child population (Steinhausen and Bis-
gaard 2014; Piovani et al. 2019) and within child welfare (Linares
et al. 2013; Vanderwerker et al. 2014). One could speculate as to
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whether this unexpected gender difference reflects the distribution of
the psychiatric disorders (particularly anxiety and depression in girls
and neurodevelopmental disorders in boys) for which treatment with
antipsychotics increasingly is considered to be an option in the
general child population (Nesvag et al. 2016; Hojlund et al. 2019)
and within child welfare services (Linares et al. 2013).
In our study, we found a shift in the use of antipsychotics from
male preponderance in childhood (< age 13) to female prepon-
derance in adolescence (age >13 years), in line with national
prescription data from 2008 to 2017 (Furu et al. 2018) (see Sup-
plementary Table S2 for details).
This shift is in line with the known epidemiological patterns
for stimulants and antidepressants, where stimulants are most fre-
quently used in boys during middle childhood and antidepressants in
adolescent girls, as was the case in our study, and for instance shown
in the New Zealand study with national prescription data from 2016
(Barczyk et al. 2020). In our study, the boys in RC used stimulants
twice as frequently as girls, and boys had high overlap in the use of
stimulants and antipsychotics (Fig. 1). The girls in RC used antide-
pressants three times more frequently than boys, with high overlap
between antidepressants and antipsychotics among the girls (Fig. 1),
and as a great majority in our study were adolescents (81%), this
probably explains the higher use of these two psychotropics.
Unfortunately, we did not have diagnostic information in our
study and were unable to check whether these assumptions explain
the gender differences in antipsychotic use. However, both the Na-
tional Patient Registry data from all Norwegian Child and Adoles-
cent Mental Health Services (Krogh et al. 2016) (from the same year
as our study) and a national study on adolescents in RC (Jozefiak
et al. 2016) underline that there is a majority of girls diagnosed with
anxiety and depressive disorders during adolescence, in contrast to
boys diagnosed with ADHD in middle childhood.
Future studies of children in RC should combine information
about psychotropic medications and the psychiatric diagnoses and
include gender-specific findings.
Strengths and limitations
A strength of the present study is the use of a national pre-
scription registry, which includes all patients treated with psy-
chotropic medication in Norway, providing valuable information
about the dispensed medication in this cohort of youth in RC and
as such may be considered representative of clinical practice.
Our study has limitations. First, we have valid data on dispensed
medication, and thus, primary nonadherence is not an issue, but we
have no knowledge of whether the child actually took the medi-
cation. Second, the NorPD only provides data for filled prescrip-
tions. Thus, since diagnostic information was not available, we
cannot report on the prevalence of psychiatric disorders. Third,
regarding co-medication, data on the different dispensed medica-
tions indicate that they are used during 2016, not necessarily at the
exact same time during that year. However, this pertains to both
populations and the comparison with the general population is fair.
Fourth, all of the children were not in RC all of 2016, and some
medications were dispensed when the children were outside RC.
Fifth, we do not have the prescribed dosages for the youth in our
study. However, for all antipsychotics the DDDs/per person/year
were lower, and for some considerably lower, than the assumed
average maintenance dose per day for a drug used long-term for
schizophrenia/bipolar disorder in adults, in line with what was
reported by clinicians in a survey of antipsychotic medication
(Rettew et al. 2015). Finally, we do not know whether the partic-
ipants were adequately assessed for the presence of psychiatric
disorders or offered recommended psychological interventions
before medication was prescribed.
Conclusions
In this representative population of youth in RC, approximately
one in four used antidepressants, antipsychotics, and/or stimu-
lants, suggesting a high prevalence of psychiatric disorders in RC.
However, given the high prevalence of psychiatric disorders pre-
viously reported in this population, the present findings do not
necessarily suggest an overtreatment with psychotropic medication
in RC. However, the frequent use of antipsychotics is a concern,
as it may reflect that the youth are not provided with the recom-
mended first-line psychological treatments for aggressive behaviors,
anxiety/depression, or sleep disorders. This concern is supported
by previous literature underlining that children within the child
welfare system generally do not receive adequately assessment and
nonpharmacological treatment. Altogether, the findings in the pres-
ent study support the need for additional studies that specifically
target medication use in conjunction with evidence-based psycho-
logical treatments to improve the diagnoses and treatments of
mental disorders in this population.
Clinical Significance
Clinicians should ensure that youth in RC are adequately as-
sessed, monitored, and also provided with suitable nonphar-
macological treatment when treating them with psychotropic
medication, particularly with antipsychotics.
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